# CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies

> **NCT05454241** · PHASE2 · COMPLETED · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 14 (actual)

## Conditions studied

- Hematological Malignancies

## Interventions

- **DRUG:** Anti-CD7 CAR-T

## Key facts

- **NCT ID:** NCT05454241
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-07
- **Primary completion:** 2024-08-31
- **Final completion:** 2024-08-31
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2025-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05454241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05454241, "CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05454241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*